Nebulized interferon-β1a (SNG001) in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials
In brief
Nebulized interferon was linked to 84% fewer COVID hospitalizations in two trials
A meta-analysis of four randomized trials involving 1,055 people found fewer hospitalizations with nebulized interferon, but that estimate came from only two trials. The analysis found no clear difference in deaths, recovery by day 28, or overall adverse events; larger trials are needed, especially in vaccinated people and those previously infected.
- Journal
- Pulmonology (Q1)
- Published
- 19 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Jinlv Qin, Guizuo Wang, Dong Han
- PMID
- 43053745
- DOI
- 10.1080/25310429.2026.2765991
Why clinicians should know about it
- Picked for Pulmonary and Respiratory Medicine (paper of the day, 22 November 2026): Systematic review evaluates nebulized treatment for COVID-19
Abstract
BACKGROUND: This systematic review and meta-analysis aimed to determine the efficacy of nebulised interferon-β1a (SNG001) in patients with Coronavirus disease-2019 (COVID-19). METHODS: A systematic search was conducted across PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Studies were searched up to November 2025. Randomised controlled trials (RCTs) on treatment of COVID-19 with SNG001, compared with placebo or standard of care, were reviewed. Data were analysed using the RevMan Version 5.1 (The Cochrane Collaboration). Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for dichotomous outcomes. RESULTS: Four RCTs (enrolling 1055 participants) met the inclusion criteria. The proportion of patients with hospitalisations (data extracted from two RCTs) (RR 0.16, 95% CI 0.03 to 0.88), and serious adverse events (RR 0.65, 95% CI 0.47 to 0.90) were significantly fewer in SNG001 groups. There was no statistically significant difference in all-cause mortality (RR 0.72, 95% CI 0.37 to 1.39), patients non-recovery at day 28 (RR 0.87, 95% CI 0.65 to 1.17), and adverse event (RR 0.97, 95% CI 0.90 to 1.04) between the two groups. CONCLUSIONS: Nebulised SNG001 was safe and associated with a reduction in COVID-19-related hospital admission. SNG001 shows a potential benefit for outpatients with COVID-19, but it requires larger clinical trials for future validations, particularly in vaccinated and previously infected populations.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.